Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 vaccine immunogenicity in Greek healthcare workers
ISRCTN61884303Phase 4Completed
- Sponsor
- G. Gennimatas General Hospital
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by G. Gennimatas General Hospital. Primary endpoint: Immunogenicity after vaccination. Started Jan 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN61884303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61884303.